Published in Blood Weekly, May 3rd, 2007
"The data that we have collected from our ongoing Phase I trial with INNO-406 demonstrate that the compound has clinical activity and is safe and well tolerated at all doses tested thus far," stated Steven Kelly, President and CEO of INNOVIVE Pharmaceuticals. "We believe we are in the therapeutic window for this agent. We will continue our Phase I study to finalize the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.